Skip to main content

Sarepta Therapeutics Value Stock - Dividend - Research Selection

Sarepta Therapeutics

ISIN: US8036071004, WKN: A1J1BH

Market price date: 28.05.2021
Market price: 75,65 USD

Sarepta Therapeutics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 05-03-2021
Cash flow
Net operating cash flow 107.466.000
Capital Expenditures -82.202.000
Free cash flow 25.264.000
Balance sheet
Total Equity 761.759.000
Liabilities & Shareholders equity 2.984.720.000
Income statement
Net income -554.128.000
Eps (diluted) -7,110
Diluted shares outstanding 79.374.200
Net sales/revenue 540.099.000

Fundamental ratios calculated on: 28-05-2021

Key figures 28-05-2021
Cash flow
P/C 55,88
P/FC 237,68
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization6.004.658.176,00 USD
IndicesNASDAQ Comp.
Raw Data SourceUS GAAP in Millionen USD
Stock Split2012-07-12,1.0000/6.0000

Description of the company

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. Its product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. It is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). It initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,